Critically, rIL-25 treatment increased tumour burden in ILC2-replete but not ILC2-deplete Apc1322T/+ mice, indicating an essential role for ILC2 in driving IL-25-mediated CRC tumorigenesis (81). Here, IL25 is linked to neoplasm.